The DOI matches its Crossref record; 142 of the 142 references it cites were found in a registry or an index.
Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy
Open accessAbstract
Head and neck squamous cell carcinomas (HNSCCs) are highly aggressive, multi-factorial tumors in the upper aerodigestive tract affecting more than half a million patients worldwide each year. Alcohol, tobacco, and HPV infection are well known causative factors for HNSCCs. Current treatment options for HNSCCs are surgery, radiotherapy, chemotherapy, or combinatorial remedies. Over the past decade, despite the marked improvement in clinical outcome of many tumor types, the overall 5-yr survival rate of HNSCCs remained ~40 - 50% largely due to poor availability of effective therapeutic options for HNSCC patients with recurrent disease. Therefore, there is an urgent and unmet need for the identification of specific molecular signatures that better predict the clinical outcomes and markers that serve as better therapeutic targets. With recent technological advances in genomic and epigenetic analyses, our knowledge of HNSCC molecular characteristics and classification has been greatly enriched. Clinical and genomic meta-analysis of multicohort HNSCC gene expression profile has clearly demonstrated that HPV+ and HPV- HNSCCs are not only derived from tissues of different anatomical regions, but also present with different mutation profiles, molecular characteristics, immune landscapes, and clinical prognosis. Here, we briefly review our current understanding of the biology, molecular profile, and immunological landscape of the HPV+ and HPV- HNSCCs with an emphasis on the diversity and heterogeneity of HNSCC clinicopathology and therapeutic responses. After a review of recent advances and specific challenges for effective immunotherapy of HNSCCs, we then conclude with a discussion on the need to further enhance our understanding of the unique characteristics of HNSCC heterogeneity and the plasticity of immune landscape. Increased knowledge regarding the immunological characteristics of HPV+ and HPV- HNSCCs would improve therapeutic targeting and immunotherapy strategies for different subtypes of HNSCCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
Ang, K. K., Harris, J., Wheeler, R., Weber, R., Rosenthal, D. I., Nguyen-Tân, P. F., Westra, W. H., Chung, C. H., Jordan, R. C., Lu, C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912217 · Cited by 6,566
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 2×
“…can also be the result of altered antigen presentation capacity of these myeloid cells as well as enhanced production of immunosuppressive cytokines and metabolites (Dhodapkar et al., 2008; Biswas and Mantovani, 2010; Gabrilovich et al., 2012; Hanahan and Coussens, 2012; Elpek et al., 2014).”
The biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Comprehensive genomic characterization of head and neck squamous cell carcinomas
The Cancer Genome Atlas Network (2015) · Nature · doi:10.1038/nature14129 · Cited by 3,877
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
Chaturvedi, A. K., Engels, E. A., Pfeiffer, R. M., Hernandez, B. Y., Xiao, W., Kim, E., Jiang, B., Goodman, M. T., Sibug-Saber, M., Cozen, W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.4596 · Cited by 3,638
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Fakhry, C., Westra, W. H., Li, S., Cmelak, A., Ridge, J. A., Pinto, H., Forastiere, A., & Gillison, M. L. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn011 · Cited by 2,779
Case–Control Study of Human Papillomavirus and Oropharyngeal Cancer
D'Souza, G., Kreimer, A. R., Viscidi, R., Pawlita, M., Fakhry, C., Koch, W. M., Westra, W. H., & Gillison, M. L. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065497 · Cited by 2,692
Puram, S. V., Tirosh, I., Parikh, A. S., Patel, A. P., Yizhak, K., Gillespie, S., Rodman, C., Luo, C. L., Mroz, E. A., Emerick, K. S., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.044 · Cited by 2,557
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,504
T cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473
Stromal fibroblasts in cancer initiation and progression
Bhowmick, N. A., Neilson, E. G., & Moses, H. L. (2004) · Nature · doi:10.1038/nature03096 · Cited by 2,302
Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny
Guilliams, M., Ginhoux, F., Jakubzick, C., Naik, S. H., Onai, N., Schraml, B. U., Segura, E., Tussiwand, R., & Yona, S. (2014) · Nature Reviews Immunology · doi:10.1038/nri3712 · Cited by 1,819
Human papillomavirus oncoproteins: pathways to transformation
Moody, C. A., & Laimins, L. A. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2886 · Cited by 1,751
Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30066-3 · Cited by 1,745 · cited 3×
“A follow up report of the longterm effects confirmed a durable response and clinical benefits in these treated patients with a 12-month ORR of higher than 71%, survival rate of 38%, and even antitumor responses in some patients lasting for longer than 30 months (Chow et al., 2016; Seiwert et al., 2016; Mehra et al., 2…”
BackgroundGillison, M. L., D'Souza, G., Westra, W., Sugar, E., Xiao, W., Begum, S., & Viscidi, R. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn025 · Cited by 1,543
Spectrum of cancer risk among US solid organ transplant recipients
Engels, E. A., Pfeiffer, R. M., Fraumeni, J. F., Kasiske, B. L., Israni, A. K., Snyder, J. J., Wolfe, R. A., Goodrich, N. P., Bayakly, A. R., Clarke, C. A., et al. (2011) · JAMA · doi:10.1001/jama.2011.1592 · Cited by 1,524
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
The molecular landscape of head and neck cancer
Leemans, C. R., Snijders, P. J. F., & Brakenhoff, R. H. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.11 · Cited by 1,395
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
Immunological hallmarks of stromal cells in the tumour microenvironment
Turley, S. J., Cremasco, V., & Astarita, J. L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3902 · Cited by 1,140
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T. (2010) · Science · doi:10.1126/science.1195300 · Cited by 1,134
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000
Recent Advances in Head and Neck Cancer
Haddad, R. I., & Shin, D. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707975 · Cited by 916
Chow, L. Q. M., Haddad, R., Gupta, S., Mahipal, A., Mehra, R., Tahara, M., Berger, R., Eder, J. P., Burtness, B., Lee, S.-H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.1478 · Cited by 857
Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells
Smyth, M. J., Thia, K. Y. T., Street, S. E. A., Cretney, E., Trapani, J. A., Taniguchi, M., Kawano, T., Pelikan, S. B., Crowe, N. Y., & Godfrey, D. I. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.4.661 · Cited by 829
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., et al. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.04.008 · Cited by 804
Lyford-Pike, S., Peng, S., Young, G. D., Taube, J. M., Westra, W. H., Akpeng, B., Bruno, T. C., Richmon, J. D., Wang, H., Bishop, J. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2384 · Cited by 777
Takeda, K., Hayakawa, Y., Smyth, M. J., Kayagaki, N., Yamaguchi, N., Kakuta, S., Iwakura, Y., Yagita, H., & Okumura, K. (2001) · Nature Medicine · doi:10.1038/83416 · Cited by 775
The head and neck cancer immune landscape and its immunotherapeutic implications
Mandal, R., Şenbabaoğlu, Y., Desrichard, A., Havel, J. J., Dalin, M. G., Riaz, N., Lee, K.-W., Ganly, I., Hakimi, A. A., Chan, T. A., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89829 · Cited by 765
A review of clinical trials of human papillomavirus prophylactic vaccines
Schiller, J. T., Castellsagué, X., & Garland, S. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.108 · Cited by 747
HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients
Castellsagué, X., Alemany, L., Quer, M., Halec, G., Quirós, B., Tous, S., Clavero, O., Alòs, L., Biegner, T., Szafarowski, T., et al. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv403 · Cited by 740
Carcinoma-associated fibroblasts: orchestrating the composition of malignancy
Gascard, P., & Tlsty, T. D. (2016) · Genes & Development · doi:10.1101/gad.279737.116 · Cited by 732
Ndiaye, C., Mena, M., Alemany, L., Arbyn, M., Castellsagué, X., Laporte, L., Bosch, F. X., de Sanjosé, S., & Trottier, H. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70471-1 · Cited by 722
Dighe, A. S., Richards, E., Old, L. J., & Schreiber, R. D. (1994) · Immunity · doi:10.1016/1074-7613(94)90087-6 · Cited by 663
Seiwert, T. Y., Zuo, Z., Keck, M. K., Khattri, A., Pedamallu, C. S., Stricker, T., Brown, C., Pugh, T. J., Stojanov, P., Cho, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3310 · Cited by 657
Badoual, C., Hans, S., Merillon, N., Van Ryswick, C., Ravel, P., Benhamouda, N., Levionnois, E., Nizard, M., Si-Mohamed, A., Besnier, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2606 · Cited by 633
Tumor neoantigens: building a framework for personalized cancer immunotherapy
Gubin, M. M., Artyomov, M. N., Mardis, E. R., & Schreiber, R. D. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80008 · Cited by 613
Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers
Badoual, C., Hans, S., Rodriguez, J., Peyrard, S., Klein, C., Agueznay, N. E. H., Mosseri, V., Laccourreye, O., Bruneval, P., Fridman, W. H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1886 · Cited by 598
Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma
Smyth, M. J., Thia, K. Y. T., Street, S. E. A., MacGregor, D., Godfrey, D. I., & Trapani, J. A. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.5.755 · Cited by 576
Expression of tumour-specific antigens underlies cancer immunoediting
DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F., & Jacks, T. (2012) · Nature · doi:10.1038/nature10803 · Cited by 529
Decreased tumor surveillance in perforin-deficient mice.
van den Broek, M. E., Kägi, D., Ossendorp, F., Toes, R., Vamvakas, S., Lutz, W. K., Melief, C. J., Zinkernagel, R. M., & Hengartner, H. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.5.1781 · Cited by 512
Burnet, M. (1957) · BMJ · doi:10.1136/bmj.1.5023.841 · Cited by 505
Kim, J. W., Wieckowski, E., Taylor, D. D., Reichert, T. E., Watkins, S., & Whiteside, T. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1010.11.3 · Cited by 497
Massarelli, E., William, W., Johnson, F., Kies, M., Ferrarotto, R., Guo, M., Feng, L., Lee, J. J., Tran, H., Kim, Y. U., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4051 · Cited by 490
Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer.
Chen, Z., Malhotra, P. S., Thomas, G. R., Ondrey, F. G., Duffey, D. C., Smith, C. W., Enamorado, I. I., Yeh, N. T., Kroog, G. S., Rudy, S., et al. (1999) · PubMed · Cited by 486
Hiraoka, K., Miyamoto, M., Cho, Y., Suzuoki, M., Oshikiri, T., Nakakubo, Y., Itoh, T., Ohbuchi, T., Kondo, S., & Katoh, H. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602934 · Cited by 481
Mehra, R., Seiwert, T. Y., Gupta, S., Weiss, J., Gluck, I., Eder, J. P., Burtness, B., Tahara, M., Keam, B., Kang, H., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0131-9 · Cited by 454
Boshoff, C., & Weiss, R. (2002) · Nature Reviews Cancer · doi:10.1038/nrc797 · Cited by 443
Harrington, K. J., Ferris, R. L., Blumenschein, G., Colevas, A. D., Fayette, J., Licitra, L., Kasper, S., Even, C., Vokes, E. E., Worden, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30421-7 · Cited by 428
Oksenhendler, E., Boulanger, E., Galicier, L., Du, M.-Q., Dupin, N., Diss, T. C., Hamoudi, R., Daniel, M.-T., Agbalika, F., Boshoff, C., et al. (2002) · Blood · doi:10.1182/blood.v99.7.2331 · Cited by 411
Hoffmann, T. K., Dworacki, G., Tsukihiro, T., Meidenbauer, N., Gooding, W. E., Johnson, J. T., & Whiteside, T. L. (2002) · PubMed · Cited by 388
Stevanović, S., Pasetto, A., Helman, S. R., Gartner, J. J., Prickett, T. D., Howie, B., Robins, H. S., Robbins, P. F., Klebanoff, C. A., Rosenberg, S. A., et al. (2017) · Science · doi:10.1126/science.aak9510 · Cited by 383
Keck, M. K., Zuo, Z., Khattri, A., Stricker, T. P., Brown, C. D., Imanguli, M., Rieke, D., Endhardt, K., Fang, P., Brägelmann, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2481 · Cited by 370
IMMUNOLOGICAL ASPECTS OF MALIGNANT DISEASE
Burnet, F. M. (1967) · The Lancet · doi:10.1016/s0140-6736(67)92837-1 · Cited by 369
Stromal features are predictive of disease mortality in oral cancer patients
Marsh, D., Suchak, K., Moutasim, K. A., Vallath, S., Hopper, C., Jerjes, W., Upile, T., Kalavrezos, N., Violette, S. M., Weinreb, P. H., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2830 · Cited by 333
Walter, V., Yin, X., Wilkerson, M. D., Cabanski, C. R., Zhao, N., Du, Y., Ang, M. K., Hayward, M. C., Salazar, A. H., Hoadley, K. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056823 · Cited by 327
Concha-Benavente, F., Srivastava, R. M., Trivedi, S., Lei, Y., Chandran, U., Seethala, R. R., Freeman, G. J., & Ferris, R. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2001 · Cited by 304
Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma
Curry, J. M., Sprandio, J., Cognetti, D., Luginbuhl, A., Bar-ad, V., Pribitkin, E., & Tuluc, M. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.03.003 · Cited by 293
Topography of cancer-associated immune cells in human solid tumors
Kather, J. N., Suarez-Carmona, M., Charoentong, P., Weis, C.-A., Hirsch, D., Bankhead, P., Horning, M., Ferber, D., Kel, I., Herpel, E., et al. (2018) · eLife · doi:10.7554/elife.36967 · Cited by 280
Frameshift events predict anti–PD-1/L1 response in head and neck cancer
Hanna, G. J., Lizotte, P., Cavanaugh, M., Kuo, F. C., Shivdasani, P., Frieden, A., Chau, N. G., Schoenfeld, J. D., Lorch, J. H., Uppaluri, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98811 · Cited by 275
Weed, D. T., Vella, J. L., Reis, I. M., De la fuente, A. C., Gomez, C., Sargi, Z., Nazarian, R., Califano, J., Borrello, I., & Serafini, P. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1711 · Cited by 261
Westra, W. H., Taube, J. M., Poeta, M. L., Begum, S., Sidransky, D., & Koch, W. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1402 · Cited by 231
HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer
Knowles, L. M., Stabile, L. P., Egloff, A. M., Rothstein, M. E., Thomas, S. M., Gubish, C. T., Lerner, E. C., Seethala, R. R., Suzuki, S., Quesnelle, K. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3252 · Cited by 231
Richardson, A. M., Havel, L. S., Koyen, A. E., Konen, J. M., Shupe, J., Wiles, W. G., Martin, W. D., Grossniklaus, H. E., Sica, G., Gilbert-Ross, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1776 · Cited by 227
Epithelial to mesenchymal transition in head and neck squamous cell carcinoma
Smith, A., Teknos, T. N., & Pan, Q. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2012.10.009 · Cited by 226
Ferris, R. L., Whiteside, T. L., & Ferrone, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2750 · Cited by 221
Gastman, B., Atarshi, Y., Reichert, T. E., Saito, T., Balkir, L., Rabinowich, H., & Whiteside, T. L. (1999) · PubMed · Cited by 216
On immunosurveillance in human cancer.
Thomas, L. (1982) · PubMed Central · Cited by 213
Reichert, T. E., Strauss, L., Wagner, E. M., Gooding, W. E., & Whiteside, T. L. (2002) · PubMed · Cited by 211
LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
Purcell, J. W., Tanlimco, S. G., Hickson, J., Fox, M., Sho, M., Durkin, L., Uziel, T., Powers, R., Foster, K., McGonigal, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0327 · Cited by 205
Lu, S.-L., Reh, D., Li, A. G., Woods, J., Corless, C. L., Kulesz-Martin, M., & Wang, X.-J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1032 · Cited by 197
Wolf, G. T., Chepeha, D. B., Bellile, E., Nguyen, A., Thomas, D., & McHugh, J. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2014.09.006 · Cited by 190
Girardi, M., Glusac, E., Filler, R. B., Roberts, S. J., Propperova, I., Lewis, J., Tigelaar, R. E., & Hayday, A. C. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021282 · Cited by 185
Kunii, N., Horiguchi, S., Motohashi, S., Yamamoto, H., Ueno, N., Yamamoto, S., Sakurai, D., Taniguchi, M., Nakayama, T., & Okamoto, Y. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01135.x · Cited by 184
Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma
Califano, J. A., Khan, Z., Noonan, K. A., Rudraraju, L., Zhang, Z., Wang, H., Goodman, S., Gourin, C. G., Ha, P. K., Fakhry, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1716 · Cited by 184
Human Papillomavirus Vaccines – Immune Responses
Stanley, M., Pinto, L. A., & Trimble, C. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.106 · Cited by 180
Carbone, D. P., Ciernik, I. F., Kelley, M. J., Smith, M. C., Nadaf, S., Kavanaugh, D., Maher, V. E., Stipanov, M., Contois, D., Johnson, B. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.158 · Cited by 169
Uchida, T., Horiguchi, S., Tanaka, Y., Yamamoto, H., Kunii, N., Motohashi, S., Taniguchi, M., Nakayama, T., & Okamoto, Y. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0373-5 · Cited by 168
Marcus, B., Arenberg, D., Lee, J., Kleer, C., Chepeha, D. B., Schmalbach, C. E., Islam, M., Paul, S., Pan, Q., Hanash, S., et al. (2004) · Cancer · doi:10.1002/cncr.20701 · Cited by 163
Yoshitake, Y., Fukuma, D., Yuno, A., Hirayama, M., Nakayama, H., Tanaka, T., Nagata, M., Takamune, Y., Kawahara, K., Nakagawa, Y., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0202 · Cited by 162
Immunobiology of head and neck cancer
Whiteside, T. L. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-5050-6 · Cited by 161
Agalliu, I., Gapstur, S., Chen, Z., Wang, T., Anderson, R. L., Teras, L., Kreimer, A. R., Hayes, R. B., Freedman, N. D., & Burk, R. D. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5504 · Cited by 161
α-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis
Hayakawa, Y., Rovero, S., Forni, G., & Smyth, M. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1630663100 · Cited by 159
The HLA crossroad in tumor immunology
Algarra, I., Cabrera, T., & Garrido, F. (2000) · Human Immunology · doi:10.1016/s0198-8859(99)00156-1 · Cited by 159
López‐Albaitero, A., Nayak, J. V., Ogino, T., Machandia, A., Gooding, W. E., DeLeo, A. B., Ferrone, S., & Ferris, R. L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.6.3402 · Cited by 156
Interactions of tumor cells with dendritic cells: balancing immunity and tolerance
Dhodapkar, M. V., Dhodapkar, K. M., & Palucka, A. K. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402247 · Cited by 154
Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer
Schuler, P. J., Harasymczuk, M., Visús, C., DeLeo, A. B., Trivedi, S., Lei, Y. L., Argiris, A. E., Gooding, W. E., Butterfield, L. H., Whiteside, T. L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2617 · Cited by 152
Cecco, L. D., Nicolau, M., Giannoccaro, M., Daidone, M. G., Bossi, P., Locati, L. D., Licitra, L. F., & Canevari, S. (2015) · Oncotarget · doi:10.18632/oncotarget.3301 · Cited by 139
Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial
Colevas, A. D., Bahleda, R., Braiteh, F., Balmanoukian, A. S., Braña, I., Chau, N. G., Sarkar, I., Molinero, L. L., Grossman, W., Kabbinavar, F. F., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy411 · Cited by 131
Srivastava, R. M., Trivedi, S., Concha‐Benavente, F., Gibson, S. P., Reeder, C., Ferrone, S., & Ferris, R. L. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0879 · Cited by 128
Wheeler, S., Shi, H., Lin, F., Dasari, S., Bednash, J. S., Thorne, S. H., Watkins, S. C., Joshi, R., & Thomas, S. M. (2013) · Head & Neck · doi:10.1002/hed.23312 · Cited by 126
Kawashiri, S., Tanaka, A., Noguchi, N., Hase, T., Nakaya, H., Ohara, T., Kato, K., & Yamamoto, E. (2009) · Head & Neck · doi:10.1002/hed.21097 · Cited by 125
Aggarwal, C., Cohen, R., Morrow, M., Kraynyak, K., Sylvester, A., Knoblock, D., Bauml, J., Weinstein, G., Lin, A., Boyer, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1763 · Cited by 124
Abbas, A. K., & Janeway, C. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81689-x · Cited by 113
Ferris, R. L., Saba, N. F., Gitlitz, B. J., Haddad, R. I., Sukari, A. W., Neupane, P. C., Morris, J. C., Misiukiewicz, K. J., Bauman, J. E., Fenton, M. J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1888 · Cited by 113
Chikamatsu, K., Sakakura, K., Toyoda, M., Takahashi, K., Yamamoto, T., & Masuyama, K. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02248.x · Cited by 108
Therapeutic Insights from Genomic Studies of Head and Neck Squamous Cell Carcinomas
Hammerman, P. S., Hayes, D. N., & Grandis, J. R. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1205 · Cited by 105
Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases
Skeate, J. G., Woodham, A. W., Einstein, M. H., Silva, D. M. D., & Kast, W. M. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1136039 · Cited by 100
Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?
Wirth, T. C., & Kühnel, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01848 · Cited by 99
Lathers, D. M. R. (2004) · Cytokine · doi:10.1016/j.cyto.2003.11.005 · Cited by 97
Lim, K. P., Cirillo, N., Hassona, Y. M., Wei, W., Thurlow, J. K., Cheong, S. C., Pitiyage, G. N., Parkinson, E. K., & Prime, S. S. (2010) · The Journal of Pathology · doi:10.1002/path.2841 · Cited by 95
Pan, M., Schinke, H., Luxenburger, E., Kranz, G., Shakhtour, J., Libl, D., Huang, Y., Gaber, A., Pavšič, M., Lenar≷cic̆, B., et al. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2006624 · Cited by 90
Shayan, G., Kansy, B., Gibson, S. P., Srivastava, R. M., Bryan, J. K., Bauman, J. E., Ohr, J. P., Kim, S., Duvvuri, U., Clump, D. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0357 · Cited by 86
Elpek, K. G., Cremasco, V., Shen, H., Harvey, C. J., Wucherpfennig, K. W., Goldstein, D. R., Monach, P. A., & Turley, S. J. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0209 · Cited by 77
Liotta, F., Querci, V., Mannelli, G., Santarlasci, V., Maggi, L., Capone, M., Rossi, M. C., Mazzoni, A., Cosmi, L., Romagnani, S., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.15 · Cited by 75
Sparano, A. M., Lathers, D. M. R., Achille, N. J., Petruzzelli, G. J., & Young, M. R. (2004) · Otolaryngology · doi:10.1016/j.otohns.2004.03.016 · Cited by 71
Five‐year relative survival for human papillomavirus‐associated cancer sites
Razzaghi, H., Saraiya, M., Thompson, T., Henley, S. J., Viens, L. J., & Wilson, R. J. (2017) · Cancer · doi:10.1002/cncr.30947 · Cited by 71
Immunity in Head and Neck Cancer
Schoenfeld, J. D. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0205 · Cited by 70
Hanna, G. J., Liu, H., Jones, R. E., Bacay, A. F., Lizotte, P. H., Ivanova, E. V., Bittinger, M. A., Cavanaugh, M. E., Rode, A. J., Schoenfeld, J. D., et al. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.02.005 · Cited by 70
Álvarez–Teijeiro, S., García–Inclán, C., Villaronga, M. Á., Casado, P., Hermida‐Prado, F., Granda‐Díaz, R., Rodrigo, J. P., Calvo, F., Del-Río-Ibisate, N., Gandarillas, A., et al. (2018) · Cancers · doi:10.3390/cancers10090334 · Cited by 64
Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy
Bedard, M., Salio, M., & Cerundolo, V. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01829 · Cited by 63
Tonella, L., Giannoccaro, M., Alfieri, S., Canevari, S., & Cecco, L. D. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0472-2 · Cited by 51
Immunomodulatory role of Keratin 76 in oral and gastric cancer
Sequeira, I., Neves, J. F., Carrero, D., Peng, Q., Palasz, N. A., Liakath‐Ali, K., Lord, G. M., Morgan, P. R., Lombardi, G., & Watt, F. M. (2018) · Nature Communications · doi:10.1038/s41467-018-05872-4 · Cited by 50
Immune alterations and immunotherapy prospects in head and neck cancer
Varilla, V., Atienza, J., & Dasanu, C. A. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.810716 · Cited by 49
Cavalieri, S., Rivoltini, L., Bergamini, C., Locati, L. D., Licitra, L. F., & Bossi, P. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.03.003 · Cited by 47
Global human papilloma virus vaccine implementation: An update
Sabeena, S., Bhat, P. V., Kamath, V. G., & Arunkumar, G. (2018) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.13634 · Cited by 42
Takami, M., Ihara, F., & Motohashi, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02021 · Cited by 36
Loose, D., Signore, A., Bonanno, E., Vermeersch, H., Dierckx, R., Deron, P. B., & de Wiele, C. V. (2008) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2007.0373 · Cited by 35
Couch, M. E., Ferris, R. L., Brennan, J. A., Koch, W. M., Jaffee, E. M., Leibowitz, M. S., Nepom, G. T., Erlich, H. A., & Sidransky, D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0682 · Cited by 34
Downregulation of Keratin 76 Expression during Oral Carcinogenesis of Human, Hamster and Mouse
Ambatipudi, S., Bhosale, P. G., Heath, E., Pandey, M., Kumar, G., KANE, S. V., Patil, A. J., Maru, G. B., Desai, R. S., Watt, F. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070688 · Cited by 27
Schuler, P. J., Börger, V., Bölke, E., Habermehl, D., Matuschek, C., Wild, C., Greve, J., Baş, M., Schilling, B., Bergmann, C., et al. (2011) · European journal of medical research · doi:10.1186/2047-783x-16-2-57 · Cited by 26
Schwab, K., Kristiansen, G., Schild, H. H., Held, S., Heine, A., & Brossart, P. (2018) · Case Reports in Oncology · doi:10.1159/000485562 · Cited by 23
Adoptive cell transfer after chemotherapy enhances survival in patients with resectable HNSCC
Jiang, P., Zhang, Y., Archibald, S. J., & Wang, H. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.05.042 · Cited by 21
Cited by
Head and neck squamous cell carcinoma
Johnson, D. E., Burtness, B., Leemans, C. R., Lui, V. W. Y., Bauman, J. E., & Grandis, J. R. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00224-3 · Cited by 4,067
Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations
Ho, A. L., Brana, I., Haddad, R., Bauman, J., Bible, K., Oosting, S., Wong, D. J., Ahn, M.-J., Boni, V., Even, C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02903 · Cited by 208
Metadata
- Authors
- Canning, M., Guo, G., Yu, M., Myint, C., Groves, M. W., Byrd, J. K., & Cui, Y.
- Venue
- Frontiers in Cell and Developmental Biology
- Publisher
- Frontiers Media SA
- Published
- 2019-04-09
- Volume
- 7
- Pages
- 52-52
- ISSN
- 2296-634X (ISSN-L)
- OpenAlex
- W2938964227
- Cited by
- 331
- References
- 142
- FWCI
- 30.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.